Case reportKidneyTreatment of Simultaneous Acute Antibody-Mediated Rejection and Acute Cellular Rejection With Alemtuzumab in Kidney Transplantation: A Case Report
Section snippets
Case Report
A 38-year-old woman with end-stage renal disease from type IV (diffuse proliferative glomerulonephritis) lupus nephritis underwent a living related donor kidney transplantation using a kidney from her cousin. The HLA mismatch was 5/6 but pretransplant T and B lymphocyte crossmatches were negative. The immunosuppressive regimen included basiliximab for induction and cyclosporine, mycophenolate sodium, and steroid as maintenance treatment. On the first posttransplant day, the kidney allograft
Discussion
Alemtuzumab, a humanized anti-CD52 specific, complement fixing, monoclonal antibody, profoundly depletes T cells, B cells, natural killer cells, and monocytes.1 Alemtuzumab was first reported by Calne et al2 to be effective for induction treatment allowing a steroid-free regimen with low doses of cyclosporine. Although there was a profound and prolonged lymphocyte depletion after alemtuzumab administration, there was no increase in the incidence of infection3 nor of posttransplantation
References (10)
- et al.
Alemtuzumab (CAMPATH-1H) induction therapy in cadaveric kidney transplantation—efficacy and safety at five year
Am J Transplant
(2005) - et al.
Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients
Transplant Proc
(2005) - et al.
Reversal of acute cellular rejection after renal transplantation with Campath-1H
Transplant Proc
(2005) - et al.
Alemtuzumab (Campath-1H): a systematic review in organ transplantation
Transplantation
(2006) - et al.
Alemtuzumab 1H allows low dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
Clinical Transplant
(1999)
Cited by (8)
Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys
2021, Transplantation ProceedingsCitation Excerpt :To date, there are no studies on alemtuzumab for late ABMR. Only 3 case reports described 5 patients with documented use of alemtuzumab for the treatment of ABMR with or without cellular rejection [26-28]. In these studies, alemtuzumab was used with plasmapheresis and IVIG, with or without rituximab.
Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'
2016, Current Opinion in Organ TransplantationAntibody-mediated rejection
2015, Current Opinion in Organ TransplantationAdvances in pharmacotherapy to treat kidney transplant rejection
2015, Expert Opinion on PharmacotherapyAntibody-mediated Rejection in Heart Transplantation
2014, Current Transplantation Reports